查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1628893

卡培他滨市场，按药物类型、适应症、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Capecitabine Market, By Drug Type, By Indication, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年卡培他滨市场规模为4.159亿美元，2024年至2032年复合年增长率为5.50%。

卡培他滨市场-市场动态

癌症发生率上升

癌细胞通常需要产生和固定 DNA。结果，癌症扩散到身体的其他部位。为了阻止癌细胞产生和修復 DNA，必须使用卡培他滨。推动卡培他滨使用的主要因素之一是癌症（包括肺癌、乳癌和其他形式）发生率的上升，以及癌症治疗药物研发（R＆D）的需求不断增长。例如，全球癌症观察站最近发布的资料显示，2020年全球报告了19,292,789例新癌症病例。其中，大肠直肠癌占10%，摄护腺癌占7.3%，胃癌占5.6%。为了阻止癌症扩散到重要的身体部位，随着全球癌症病例数量的增加，卡培他滨变得越来越必要。因此，这有助于市场的扩大。

卡培他滨市场 - 主要见解

根据我们的研究分析师分享的分析，全球卡培他滨市场预计在预测期内（2024-2032）每年将以 5.50% 左右的复合年增长率成长

根据药物类型细分，预计品牌类别将在 2023 年显示最大的卡培他滨市场份额

根据适应症细分，乳癌是2023年的主导细分市场

按地区划分，北美是 2023 年的主要收入来源

卡培他滨市场-細項分析：

全球卡培他滨市场根据药物类型、适应症、最终用户和地区进行细分。

适应症细分为乳癌、胰臟癌、大肠癌、胃癌等几类。 2023年，乳癌细分市场在卡培他滨市场中占据最大的市场份额。医疗机构使用卡培他滨治疗先前治疗后復发的乳癌，并已进展到颈部、胸部和其他区域周围的淋巴结和组织。卡培他滨也用于治疗早期三阴性乳癌。例如，在欧洲男性人口中，发现了 2,339,617 例新病例。 2020年，乳癌占欧洲诊断的所有癌症病例的12.07%，成为最常见的癌症类型。因此，随着乳癌病例数的增加，对卡培他滨阻止乳癌扩散的需求也增加。由于这一重要因素，市场正在扩大。

最终用户市场分为多个类别，例如医院、专科诊所、家庭护理等。 2023年，医院细分市场在卡培他滨市场中占据最大的市场份额。许多癌症化疗方案的关键要素是卡培他滨。因此，卡培他滨在医院用于治疗多种癌症，如大肠癌、晚期和转移性乳癌等。

卡培他滨市场-地理洞察

从地理来看，卡培他滨市场广泛分布于北美、拉丁美洲、欧洲、亚太地区、中东和非洲地区。这些区域根据开展业务的国家进一步划分。

2023年，北美在卡培他滨产业中占据最大的市场份额。例如，美国癌症协会估计，美国每年发现 800 至 900 例骨肉瘤（一种影响骨骼的癌症）新病例，其中一半病例发生在青少年身上。因此，北美不断增长的癌症病例正在支持该地区卡培他滨市场的扩张。

此外，由于医疗保健成本上升、医疗保健服务范围扩大以及癌症发病率上升，卡培他滨市场在亚太地区正在迅速扩张。由于这些地区的政府和医疗保健专业人员意识到卡培他滨等口服化疗药物对于提高患者便利性和治疗效果的重要性，因此在临床实践中得到越来越广泛的使用。

卡培他滨市场-竞争格局：

卡培他滨市场竞争极为激烈，有许多大公司以及大量中小企业，如 Teva Pharmaceutical Industries Ltd.、F. Hoffmann-La Roche Ltd.、Mylan NV、Pfizer Inc.（美国） ）、赛诺菲（法国）等。这些企业由于其广泛的产品和分销系统而拥有强大的研发能力和重要的市场占有率。该市场的竞争非常激烈，企业专注于扩大产品线并透过合作、併购和收购来获得市场份额。例如，生产该药物的印度公司 Dr. Reddy's Laboratories Ltd. 于 2021 年 2 月在美国市场推出了希罗达（卡培他滨）片剂的仿製药。因此，由于全球市场产品供应的增加，卡培他滨市场正在成长。

最新进展：

2023 年 1 月：德国製药公司 Cheplapharm Arzneimittel GmbH 以未公开的金额从 F. Hoffmann-La Roche AG 购买了希罗达（卡培他滨）在中国的营销权。 Cheplapharma 希望透过此次收购增加其在製药业的市场份额并强化其癌症产品组合。位于瑞士的製药公司 F. Hoffmann-La Roche AG 生产口服化疗药物卡培他滨，也称为希罗达。

2022 年 12 月：Shilpa Medicare 推出了一种 90 秒溶解的卡培他滨分散丸，用于治疗大肠直肠癌和转移性乳癌。透过增加市场收入，该产品的推出有助于公司实现产品多元化。

目录

第 1 章：卡培他滨市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 卡培他滨市场片段（依药物类型）
    • 卡培他滨市场片段（按适应症）
    • 最终用户的卡培他滨市场片段
    • 卡培他滨市场片段（依国家）
    • 卡培他滨市场片段（按地区）
  • 竞争洞察

第 3 章：卡培他滨主要市场趋势

  • 卡培他滨市场驱动因素
    • 市场驱动因素的影响分析
  • 卡培他滨市场限制
    • 市场限制影响分析
  • 卡培他滨市场机会
  • 卡培他滨市场未来趋势

第 4 章：卡培他滨产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：卡培他滨市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：卡培他滨市场格局

  • 2023 年卡培他滨市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：卡培他滨市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 通用的
    • 品牌化

第 8 章：卡培他滨市场 - 依适应症分类

  • 概述
    • 按指标分類的细分市场占有率分析
    • 乳癌
    • 胰腺癌
    • 大肠直肠癌
    • 胃癌
    • 其他的

第 9 章：卡培他滨市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 专科诊所
    • 居家护理
    • 其他的

第 10 章：卡培他滨市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 卡培他滨北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模和预测（按指标）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 卡培他滨欧洲主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模与预测（按指标）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 卡培他滨亚太地区主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类型）
    • 亚太地区市场规模与预测（依指标）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 韩国
    • 日本
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 卡培他滨拉丁美洲主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模与预测（按指标）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 卡培他滨中东和非洲主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（依指标）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析-卡培他滨产业

  • 竞争仪表板
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.(Israel)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Mylan NV (US)
    • Pfizer Inc. (US.)
    • Sanofi (France)
    • Bayer AG (Germany)
    • Lilly (US.)
    • Sun Pharmaceutical Industries Ltd. (India)
    • GSK plc (UK.)
    • Novartis AG (Switzerland)
    • Merck & Co., Inc. (US.)
    • Alkem Labs Ltd (India)
    • Aurobindo Pharma (India)
    • Lupin (India)
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4422

REPORT HIGHLIGHT

Capecitabine Market size was valued at USD 415.9 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

Capecitabine is an oral chemotherapy medication, which is used to treat a number of malignancies, such as those of the breast, colon, and rectal region. It is a member of the antimetabolite medication class, which inhibits the development and transmission of cancer cells. Since capecitabine is a prodrug, the body transforms it into 5-fluorouracil (5-FU), which is its active form. After being transformed, 5-FU stops cancer cells from making DNA and RNA, which eventually kills the cells. Capecitabine, which is typically given as pills, is taken orally as opposed to intravenously as conventional chemotherapy medications. The increase in the older population, the rise in cancer prevalence, and the intense research and development efforts to assess novel pharmacological uses of capecitabine are the main factors propelling the market's expansion. Additionally, the market is rising due to factors like the expansion of new cancer institutions, increased expenditure in cancer research, and others that are driving up demand for capecitabine. Furthermore, the market will rise even more during the projection period due to the growing development of new capecitabine product categories.

Capecitabine Market- Market Dynamics

Rising Incidence of Cancer

It is often necessary for the cancer cells to produce and fix DNA. As a result, cancer spreads to other body parts. In order to stop cancer cells from creating and repairing DNA, capecitabine must be used. One of the main factors propelling the use of capecitabine is the rising incidence of cancer, including lung, breast, and other forms, as well as the growing need for pharmaceutical research and development (R&D) for cancer therapy. For instance, the Global Cancer Observatory recently released data showing that 19,292,789 new cases of cancer were reported worldwide in 2020. With 11.7% of all cases, breast cancer was the most frequent type of cancer in 2020. Lung cancer came in second with 11.4%, colorectum cancer with 10%, prostate cancer with 7.3%, and stomach cancer with 5.6%. In order to stop cancer from spreading to important body parts, capecitabine is becoming more and more necessary as the number of cancer cases worldwide rises. Consequently, this is contributing to the expansion of the market.

Capecitabine Market- Key Insights

As per the analysis shared by our research analyst, the global Capecitabine Market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on drug type segmentation, the branded category was predicted to show maximum Capecitabine Market share in the year 2023

Based on indication segmentation, the breast cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Capecitabine Market- Segmentation Analysis:

The Global Capecitabine Market is segmented on the basis of Drug Type, Indication, End-user, and Region.

The indication segment is divided into several categories, including Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer, and Others. In 2023, the breast cancer segment held the largest market share in the capecitabine market. Healthcare facilities use capecitabine to treat breast cancer that has returned after prior treatment and has progressed to the lymph nodes and tissues surrounding the neck, chest, and other areas. Capecitabine is also used to treat triple-negative breast cancer in its early stages. For instance, in the male population of Europe, 2,339,617 new cases were detected. Breast cancer accounted for 12.07% of all cancer cases diagnosed in Europe in 2020, making it the most frequent kind. Therefore, the need for capecitabine to stop the spread of breast cancer is growing as the number of cases of the disease rises. The market is expanding as a result of this important element.

The end-user market is divided into various categories, such as Hospitals, Specialty Clinics, Homecare, and Others. The hospitals' segment held the largest market share in the capecitabine market in 2023. Several international governmental authorities, including the European Union and the US Food and Drug Administration (FDA), have approved the use of capecitabine. A key element of many cancer chemotherapy regimens is capecitabine. As a result, capecitabine is used in hospitals to treat a variety of cancers, such as colorectal cancer, advanced and metastatic breast cancer, and others.

Capecitabine Market- Geographical Insights

Geographically, the Capecitabine Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

North America held the largest market share in the capecitabine industry in 2023. The rising incidence of cancer cases, the increased creation of new products, and other factors are blamed for this trend. For instance, the American Cancer Society estimates that between 800 and 900 new cases of osteosarcoma, a bone-affecting cancer, are discovered in the US annually, with half of those cases occurring in adolescents and teenagers. Consequently, the growing number of cancer cases in North America is supporting the expansion of the capecitabine market in the area.

In addition, the market for capecitabine is expanding quickly in Asia-Pacific due to the rising healthcare costs, expanded access to healthcare services, and rising cancer incidence rates. Oral chemotherapy medications like capecitabine are becoming more widely used in clinical practice as a result of governments and healthcare professionals in these areas realizing how important they are for enhancing patient convenience and treatment outcomes.

Capecitabine Market- Competitive Landscape:

The market for capecitabine is extremely competitive, with many major companies as well as a huge number of small and medium-sized businesses such as Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Mylan N.V., Pfizer Inc. (US), Sanofi (France), and others. These businesses have robust R&D capacities and a significant market presence due to their wide range of products and distribution systems. The market is notoriously competitive, with businesses concentrating on growing their product lines and gaining market share through partnerships, mergers, and acquisitions. For instance, the generic form of Xeloda (capecitabine) tablets was introduced in the US market in February 2021 by Dr. Reddy's Laboratories Ltd., an Indian company that manufactures the medication. Therefore, the capecitabine market is growing as a result of the increase in product offerings in the global market.

Recent Developments:

January 2023: For an undisclosed sum, Cheplapharm Arzneimittel GmbH, a pharmaceutical firm based in Germany, purchased the marketing rights to Xeloda (capecitabin) in China from F. Hoffmann-La Roche AG. Through the acquisition, Cheplapharma hopes to increase its market share in the pharmaceutical industry and fortify its cancer portfolio. The pharmaceutical business F. Hoffmann-La Roche AG, situated in Switzerland, manufactures the oral chemotherapy medication capecitabine, also known as Xeloda.

December 2022: A 90-second-dissolving Capecitabine dispersible pill for the treatment of colorectal and metastatic breast cancer was introduced by Shilpa Medicare. By increasing market revenue, the product's launch aids the corporation in diversifying its offerings.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAPECITABINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Teva Pharmaceutical Industries Ltd.(Israel)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (US.)
  • Sanofi (France)
  • Bayer AG (Germany)
  • Lilly (US.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • GSK plc (UK.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (US.)
  • Alkem Labs Ltd (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Others

GLOBAL CAPECITABINE MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Generic
  • Branded

GLOBAL CAPECITABINE MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Others

GLOBAL CAPECITABINE MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

GLOBAL CAPECITABINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The US.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Capecitabine Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Capecitabine Market Snippet by Drug Type
    • 2.1.2. Capecitabine Market Snippet by Indication
    • 2.1.3. Capecitabine Market Snippet by End-user
    • 2.1.4. Capecitabine Market Snippet by Country
    • 2.1.5. Capecitabine Market Snippet by Region
  • 2.2. Competitive Insights

3. Capecitabine Key Market Trends

  • 3.1. Capecitabine Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Capecitabine Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Capecitabine Market Opportunities
  • 3.4. Capecitabine Market Future Trends

4. Capecitabine Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Capecitabine Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Capecitabine Market Landscape

  • 6.1. Capecitabine Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Capecitabine Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Generic
    • 7.1.3. Branded

8. Capecitabine Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Breast Cancer
    • 8.1.3. Pancreatic Cancer
    • 8.1.4. Colorectal Cancer
    • 8.1.5. Gastric Cancer
    • 8.1.6. Others

9. Capecitabine Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Specialty Clinics
    • 9.1.4. Homecare
    • 9.1.5. Others

10. Capecitabine Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Capecitabine Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Capecitabine Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Capecitabine Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Capecitabine Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Capecitabine Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Capecitabine Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Teva Pharmaceutical Industries Ltd.(Israel)
    • 11.2.2. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 11.2.3. Mylan N.V. (U.S.)
    • 11.2.4. Pfizer Inc. (US.)
    • 11.2.5. Sanofi (France)
    • 11.2.6. Bayer AG (Germany)
    • 11.2.7. Lilly (US.)
    • 11.2.8. Sun Pharmaceutical Industries Ltd. (India)
    • 11.2.9. GSK plc (UK.)
    • 11.2.10. Novartis AG (Switzerland)
    • 11.2.11. Merck & Co., Inc. (US.)
    • 11.2.12. Alkem Labs Ltd (India)
    • 11.2.13. Aurobindo Pharma (India)
    • 11.2.14. Lupin (India)
    • 11.2.15. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us